Peter Ver Lee, MD
Cardiovascular Disease · Bangor, MENPI 1760453344
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 65.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $168 and has fallen 56.0% since, to $74 in 2024.
Across 4 payments — averaging $81.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$214
- Shockwave Medical, Inc$86
- Biotronik Inc.$28
Across 490 payments — averaging $451.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$137K
- Biotronik Inc.$84K
What the payments were for
- Food & beverage$327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $214 |
| Shockwave Medical, Inc | 1 | $86 |
| Biotronik Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CROSSBOSS$140
How this compares
$327 in reported general payments places this provider in the 60th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 36 | $59,826 |
| EliquisApixaban | 25 | $38,413 |
| Dofetilide | 24 | $9,738 |
| Ranolazine ErRanolazine | 23 | $1,905 |
| Metoprolol Succinate | 55 | $896 |
| SotalolSotalol Hcl | 33 | $701 |
| ClopidogrelClopidogrel Bisulfate | 37 | $642 |
| Flecainide Acetate | 11 | $538 |
| Amiodarone Hcl | 38 | $456 |
| Rosuvastatin Calcium | 14 | $323 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 20 | $237 |
| Nitroglycerin | 19 | $211 |
| Carvedilol | 18 | $138 |
| Losartan Potassium | 13 | $87 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bangor
- Christopher LangBangor$3K
- Sverrir GunnarssonBangor$2K
- Eddy KarnabiBangor$2K
- Chae ChoiBangor$2K
- Rupert FinckeBangor$2K
- Thorarinn BjarnasonBangor$741
- Alan WisemanBangor$583
- Qurat Ul Ain JelaniBangor$429
- Christine RutlenBangor$364
- Jims Jean-JacquesBangor$285
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.